UK Markets close in 6 hrs 30 mins

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
103.24-2.80 (-2.64%)
At close: 04:00PM EDT
105.53 +2.29 (+2.22%)
Pre-market: 04:38AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close106.04
Open103.22
Bid105.11 x 800
Ask105.21 x 1100
Day's range102.16 - 104.27
52-week range78.71 - 122.16
Volume1,860,750
Avg. volume1,481,323
Market cap235.344B
Beta (5Y monthly)0.32
PE ratio (TTM)34.01
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.57 (1.48%)
Ex-dividend date25 Mar 2022
1y target estN/A
  • Globe Newswire

    Novo Nordisk A/S: Share repurchase programme

    Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate

  • Globe Newswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

    Bagsværd, Denmark, 11 May 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated perso

  • Globe Newswire

    Novo Nordisk A/S:

    Novo Nordisk – major shareholder announcement Bagsværd, Denmark, 6 May 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 29 April 2022 holds B shares equal to 5.06% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 3